**Abstract**

***Objective:*** Long-acting injectable antipsychotic (LAI) provides a potential solution to overcome poor adherence to medication in patients with schizophrenia or bipolar disorder. Quality of life (QoL) is the general feelings of well-being of individuals. In this study, we measured the QoL in patients with schizophrenia or bipolar disorder who were receiving LAI treatment.

***Methods:*** 434 patients with schizophrenia and 42 patients with bipolar disorder received LAI treatment for at least 6 months regularly at Taipei City Psychiatric Center were administered with Brief World Health Organization's Quality of Life (WHOQoL), Chinese Health Questionnaire (CHQ), Subjective Well-being under Neuroleptics (SWN) and Social Performance scale (PSP) in a cross-sectional interview.

***Results:*** The duration of LAI treatment was 8.6 ± 8.9 years for schizophrenia and 5.5 ± 7.5 years for bipolar disorder, with total scores of WHOQoL 50.4 ± 8.9 and 52.1 ± 8.9, respectively (Norm: 56.1 in Taiwan). There was no difference in WHOQOL, CHQ between the two groups, while the bipolar patients had slightly higher SWN (81.8 ± vs 13.278.1 ± 12.2, P= 0.060) and significant PSP scores (74.6 ± 5.8 vs 71.0 ± 5.9, P\<0.001). The Frequency of hospitalization (times/year) were significantly decreased after LAI treatment in schizophrenia (0.26 ± 0.42 to 0.09 ± 0.24) and bipolar disorder (0.56 ± 0.67 to 0.15 ± 0.39).

***Conclusions:*** LAI treatment can efficaciously prevent the relapse of psychotic or mood episodes in patients with poor adherence to medications. Patients with bipolar disorders reported a slightly higher satisfaction, in terms of SWN and PSP, but not QoL and CHQ, than patients with schizophrenia. These results suggest that patients with schizophrenia or bipolar disorder can have an acceptable level of QoL when they are under a regular adherence to medications.
